Inactive Instrument

NEOVACS Stock Xetra

0LW

FR0004032746

Biotechnology & Medical Research

End-of-day quote Xetra Other stock markets
- ^EUR	-

02-11	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
11-21	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI

News in other languages: NEOVACS

06-15	Financements dilutifs et fonds vautours : le législateur s'en mêle enfin
05-22	Bourse : Richemont brille, Estée Lauder renonce à Puig, Kioxia grossit
05-22	L'IA reprend le leadership
05-04	Bourse : GameStop veut racheter Ebay, game over pour Spirit, Engie accélère dans l'éolien
05-04	Coup de théâtre ou coup d'épée dans l'eau ?

More news

Managers and Directors: NEOVACS

Manager	Title	Age	Since
Hugo Brugière CEO	Chief Executive Officer	-	-
Alexandre Courtoux DFI	Director of Finance/CFO	-	01/10/2020
Laurent Reber CTO	Chief Tech/Sci/R&D Officer	56	-

Director	Title	Age	Since
Jean-Jacques Bertrand CHM	Chairman	87	28/05/2003
Baudouin Hallo BRD	Director/Board Member	-	01/05/2020
Hugo Brugière CHM	Chairman	-	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+2.56%	+7.12%	-7.30%	-0.26%	44.45B
REVOLUTION MEDICINES, INC.	+0.15%	+7.61%	+324.11%	+565.24%	36.04B
BEONE MEDICINES AG	+0.36%	+5.50%	+3.87%	+54.57%	30.7B
IQVIA HOLDINGS INC.	+8.37%	+8.76%	+17.05%	-13.29%	28.59B
CELLTRION, INC.	+7.60%	-1.09%	+12.49%	+20.82%	23.01B
ASCENDIS PHARMA A/S	-0.24%	+2.97%	-	-	14.82B
MEDPACE HOLDINGS, INC.	+8.30%	+12.19%	+62.65%	+129.55%	13.52B
EUROFINS SCIENTIFIC SE	+2.73%	+7.16%	+11.00%	+18.45%	12.98B
IONIS PHARMACEUTICALS, INC.	+0.70%	+2.97%	+93.04%	+93.04%	12.56B
Average	+3.39%	+4.61%	+64.61%	+108.52%	24.07B
Weighted average by Cap.	+3.22%	+4.99%	+71.38%	+125.31%

See all sector performances

Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company focuses its development effort on two Kinoids for Crohnâ€™s disease, Rheumatoid Arthritis and lupus disease. Neovacs SAâ€™s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The Company operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.

Employees

Sector

Biotechnology & Medical Research

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	4.09K 4.64K 3.77K 3.53K 6.61K 438K 6.73K 45.33K 17.56K 216K 17.44K 17.06K 751K	P/E 2023 *	-	P/E 2024	-
Enterprise Value	-201K -228K -185K -173K -325K -21.52M -331K -2.23M -863K -10.62M -857K -839K -36.93M	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	0.01%	Yield 2023 *	-	Yield 2024	-

02-11	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
11-21	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
21/10/25	Neovacs S.A. announced that it expects to receive ?0.25 million in funding	CI
12/08/25	Neovacs S.A. announced that it has received ?0.25 million in funding from European High Growth Opportunities Manco S.A.	CI
30/04/25	Neovacs S.A. Auditor Raises 'Going Concern' Doubt	CI
30/04/25	Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
17/03/25	Neovacs S.A. announced a financing transaction	CI
04/02/25	Neovacs: consideration of delisting, share price surges
04/11/24	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
01/11/24	Tech's Tangled Path with Microsoft
17/06/24	Neovacs: collaboration agreement with CNRS
10/06/24	Neovacs: presents results from vaccine candidates
04/06/24	Néovavs: raises 200,000 euros through the issue of OCEANE-BSA bonds

	2023	2024
Net sales	533K 606K 492K 460K 862K 57.11M 878K 5.91M 2.29M 28.17M 2.27M 2.23M 98.01M	434K 493K 400K 374K 701K 46.46M 714K 4.81M 1.86M 22.92M 1.85M 1.81M 79.74M
Net income	-8.74M -9.93M -8.06M -7.54M -14.13M -936M -14.4M -96.92M -37.54M -462M -37.29M -36.48M -1.61B	-32.91M -37.39M -30.36M -28.39M -53.2M -3.52B -54.19M -365M -141M -1.74B -140M -137M -6.05B
Net Debt	-237K -269K -218K -204K -382K -25.32M -389K -2.62M -1.02M -12.49M -1.01M -987K -43.46M	-205K -233K -189K -177K -331K -21.96M -338K -2.27M -881K -10.83M -875K -856K -37.68M

NEOVACS Stock Xetra

Stocks

0LW

FR0004032746

Biotechnology & Medical Research

Valuation: NEOVACS

Latest news : NEOVACS

News in other languages: NEOVACS

Managers and Directors: NEOVACS

Other Biotechnology & Medical Research

Financials

Company Profile